The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, Rapalink-1, a compound in which a mTOR kinase inhibitor is linked to rapamycin, and delivered at low dose, has shown the ability to inhibit mTORC1 kinase activity selectively 190.”
From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [190]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Self-citationMaking new contacts: the mTOR network in metabolism and signalling crosstalk
Shimobayashi, M., & Hall, M. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3757 · Cited by 1,053
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. (2016) · Nature · doi:10.1038/nature17963 · Cited by 479
Self-citation
Flagged first, then by citations
Research works printed but not linked: 21
- Baretić, 2014, The structural basis for mTOR function, Semin. Cell Dev. Biol., 36, 91, 10.1016/j.semcdb.2014.09.024 · DOI
- Bradshaw, 2015, Prolonged and tunable residence time using reversible covalent kinase inhibitors, Nat. Chem. Biol., 11, 525, 10.1038/nchembio.1817 · DOI
- Choi, 1996, Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP, Science, 273, 239, 10.1126/science.273.5272.239 · DOI
- Fan, 2006, A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma, Cancer Cell, 9, 341, 10.1016/j.ccr.2006.03.029 · DOI
- Fan, 2007, A dual phosphoinositide-3-kinase {alpha}/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma, Cancer Res., 67, 7960, 10.1158/0008-5472.CAN-07-2154 · DOI
- Fan, 2009, EGFR signals to mTOR through PKC and independently of Akt in glioma, Sci. Signal, 2, ra4, 10.1126/scisignal.2000014 · DOI
- Feldman, 2009, Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2, PLoS Biol., 7, e38, 10.1371/journal.pbio.1000038 · DOI
- Folkes, 2008, The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer, J. Med. Chem., 51, 5522, 10.1021/jm800295d · DOI
- Garcia-Martinez, 2009, Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR), Biochem. J., 421, 29, 10.1042/BJ20090489 · DOI
- Gaubitz, 2015, Molecular basis of the rapamycin insensitivity of target of rapamycin complex 2, Mol. Cell, 58, 977, 10.1016/j.molcel.2015.04.031 · DOI · Paper page
- Hirai, 2010, MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo, Mol. Cancer Ther., 9, 1956, 10.1158/1535-7163.MCT-09-1012 · DOI
- Houghton, 2010, Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program, Mol. Cancer Ther., 9, 101, 10.1158/1535-7163.MCT-09-0952 · DOI
- Ilagan, 2016, Emerging role of mTOR in the response to cancer therapeutics, Trends Cancer, 2, 241, 10.1016/j.trecan.2016.03.008 · DOI
- MacMillan, 2013, FK506 binding proteins: cellular regulators of intracellular Ca2+ signalling, Eur. J. Pharmacol., 700, 181, 10.1016/j.ejphar.2012.12.029 · DOI
- Nagane, 1998, Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases, Proc. Natl. Acad. Sci. USA, 95, 5724, 10.1073/pnas.95.10.5724 · DOI
- Omuro, 2013, Glioblastoma and other malignant gliomas: a clinical review, JAMA, 310, 1842, 10.1001/jama.2013.280319 · DOI
- Sarkaria, 2006, Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response, Clin. Cancer Res., 12, 2264, 10.1158/1078-0432.CCR-05-2510 · DOI · Paper page
- Sato, 2010, Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer, Oncogene, 29, 2746, 10.1038/onc.2010.28 · DOI
- Sun, 2005, Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition, Cancer Res., 65, 7052, 10.1158/0008-5472.CAN-05-0917 · DOI
- Swartling, 2010, Pleiotropic role for MYCN in medulloblastoma, Genes Dev., 24, 1059, 10.1101/gad.1907510 · DOI
- Taylor, 2012, Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance, Curr. Cancer Drug Targets, 12, 197, 10.2174/156800912799277557 · DOI
Cited by
Sorted by citations
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
mTOR at the nexus of nutrition, growth, ageing and disease
Liu, G. Y., & Sabatini, D. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0199-y · Cited by 2,737
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
Madeo, F., Carmona-Gutierrez, D., Hofer, S. J., & Kroemer, G. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.018 · Cited by 630
mTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
Metadata
- Authors
- Fan, Q., Aksoy, O., Wong, R. A., Ilkhanizadeh, S., Novotny, C. J., Gustafson, W. C., Truong, A. Y.-Q., Cayanan, G., Simonds, E. F., Haas-Kogan, D., Phillips, J. J., Nicolaides, T., Okaniwa, M., Shokat, K. M., & Weiss, W. A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 31
- Issue
- 3
- Pages
- 424-435
- ISSN
- 1535-6108
- PMC
- PMC5386178
- Cited by
- 180
- References
- 7
- Language
- en
- Licence
- Funders
- NIH (R01NS091620, R01NS089868, R01CA148699, U01CA176287, P30CA82103, U54CA163155, P50AA017072)
- Kura Oncology
- Children’s Tumor
- CureSearch
- Ross K. MacNeill
- Samuel Waxman Cancer Research Foundations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
